City

Boston (1)

New York (1)

Philadelphia (1)

Seattle (1)

Overall Status

Recruiting (2)

Not yet recruiting (1)

Suspended (1)

Phase

phase 1 (2)

n/a (1)

phase 3 (1)

Sponsor

General Oncology, Inc. (1)

Olema Pharmaceuticals, Inc. (1)

Thomas Jefferson University (1)

University of Washington (1)

Collaborator

Breast Cancer Alliance (1)

Myriad Genetics, Inc. (1)

National Cancer Institute (NCI) (1)

United States Department of Defense (1)

Study Documents

Intervention Type

drug (2)

other (2)

biological (1)

device (1)

Funder Type

Industry (2)

Other (2)

Study Type

Interventional (4)

her2 negative breast carcinoma

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (OP-1250, Fulvestrant, Anastrozole)

Not yet recruiting

Breast Cancer
+4 more

OP-1250
+4 more

(no location specified)

Aug 31, 2023

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Suspended

Anatomic Stage I Breast Cancer AJCC v8
+23 more

Short-Term Fasting
Chemotherapy

Philadelphia, Pennsylvania

Sidney Kimmel Cancer Center at Thomas Jefferson University

Jan 23, 2023

Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation Trial in Boston, New York (Melphalan, BCNU, Vitamin B12B)

Recruiting

Pancreatic Adenocarcinoma Metastatic
+14 more

Melphalan
+5 more

Boston, Massachusetts
+1 more

Dec 6, 2022

HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer Trial in Seattle

Recruiting

HER2 Negative Breast Carcinoma
+6 more

CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Laboratory Biomarker Analysis

Seattle, Washington

Fred Hutch/University of Washington Cancer Consortium

Feb 18, 2022